The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Cross-reaction has been reported with ILD from both lorlatinib and brigatinib in the same patient (PMID 31668321)
Publications
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Nov;14;e247-e248 — 2019 Nov — e247-e248
Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Sep;14;1547-1555 — 2019 Sep — 1547-1555
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
Clinical lung cancer 2018 03;19;e151-e161 — 2018 03 — e151-e161
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
The Lancet. Oncology 2016 Dec;17;1683-1696 — 2016 Dec — 1683-1696